The stock of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been Upgraded to Buy from Hold by Argus in its latest research note that was published on August 12. ZBH was given a price target of$160 by Argus, with other Wall Street analysts also giving their reports regarding the stock. Barclays analysts bumped their recommendation on ZBH stock from Underweight to Equal Weight in a separate flash note to investors on July 30. Analysts at Robert W. Baird issued an upgrade fromNeutral to Outperform for the stock, in a research note that dated back to July 29.
Zimmer Biomet Holdings, Inc. currently have the market capitalization of above $29 Billion, published in its last quarter earnings report.
ZBH surged by $2.71 during the normal trading session on Thursday and reaching a high of $143.00 during the day while it closed the day at $142.61. The Zimmer stock had a low trading volume of 1.17 million shares on that day, which is low compared to the average daily volume of 1.21M shares. ZBH has also gained 2.20% of its value over the past 7 days. However, the stock has surged by 19.05% in the 3 months of the year. Over the past six months meanwhile, it has gained 16.00% while it has added 37.50% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -0.27% from its 3 months high price. However, taking another look at ZBH will indicate that it is trading +24.87% away from its 90-day low. Looking at the bigger picture, the Zimmer Biomet Holdings, Inc. stock has dropped by -0.27% from its 52-week high while it has surged by +47.04% from its 52-week low price.
On September 09, 2019 Deltort Didier, President, EMEA sold 444 shares of the company. The average price for that transaction was $139.47 per share, which meant that Deltort Didier earned $61924.68 selling the stocks. The sale was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Sr. VP/Gen Counsel/Secretary, Phipps Chad F selling 7000 shares of this stock on August 29, 2019. The average selling price for the stock was $138.28 per share, with the sold stock accruing $967960. Following this transaction, the Sr. VP/Gen Counsel/Secretary Phipps Chad F now holds 1554 shares of the company, which is worth around $218010.7.
Zimmer has around 403 Billion cash on their books at the moment. This figure will have to be compared and looked into, with their current liabilities standing at $4 Trillion. The Zimmer stock is bringing in revenue of over 12 months, which is roughly 1 Trillion. Despite all that, Zimmer Biomet Holdings, Inc. is seeing things declining very much as their y-o-y quarterly revenue dropped by -1.17%.
Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 98.54%. This figure is better than the company’s 20-day Raw Stochastic average which currently stands at 96.08%. Over the past 20 days, Zimmer’s Stochastic %K stood at 83.55% while its Stochastic %D was revealed to be 74.33%.